Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Summary: Monoclonal antibodies have become a general modality in therapeutic development, and a variety of monoclonal antibodies targeting soluble antigens have been developed. However, even with infinite binding affinity to an antigen, a conventional antibody can bind to the antigen only once and results in an increase in total plasma antigen concentration in vivo. This antibody‐mediated antigen accumulation generally occurs because the clearance from circulation of an antibody–antigen complex is much slower than that of a free antigen. This limitation has recently been overcome by sweeping antibodies, which are capable of actively eliminating soluble antigens from circulation. A sweeping antibody incorporates two antibody engineering technologies: one is variable region engineering to enable the antibody to bind to an antigen in plasma and dissociate from the antigen in endosome (after which the antigen undergoes lysosomal degradation), and the other is constant region engineering to increase the cellular uptake of the antibody–antigen complex into endosome. By enhancing the elimination of soluble antigens from circulation, sweeping antibodies can therapeutically target soluble antigens that conventional antibodies cannot. This review discusses the features, engineering technologies, advantages, and applications of sweeping antibodies that target soluble antigens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Structure of the LDL Receptor Extracellular Domain at Endosomal pH
Rudenko, G., Henry, L., Henderson, K., Ichtchenko, K., Brown, M. S., Goldstein, J. L., & Deisenhofer, J. (2002) · Science · doi:10.1126/science.1078124 · Cited by 482 · cited 1×
“The subsequent change in pH in the endosome then triggers a conformational change in the LDL receptor (26).”
BackgroundRobbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
Computational design of antibody-affinity improvement beyond in vivo maturation
Lippow, S. M., Wittrup, K. D., & Tidor, B. (2007) · Nature Biotechnology · doi:10.1038/nbt1336 · Cited by 342 · cited 1×
“To date, various approaches for affinity maturation have been reported (4, 90); however, even if a conventional antibody had infinite affinity, it would need to be at a concentration higher than that of the total antigen to neutralize that antigen in vivo, which is the limitation of a conventional antibody.”
BackgroundAlbumin Binding to FcRn: Distinct from the FcRn−IgG Interaction
Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M., & Anderson, C. L. (2006) · Biochemistry · doi:10.1021/bi052628y · Cited by 290 · cited 1×
“As the binding of IgG and albumin to FcRn is strictly controlled by the pH, IgG and albumin can bind to FcRn only at acidic pH and show negligible binding to FcRn at neutral pH (37, 38).”
BackgroundAn Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282 · cited 1×
“Fc variants of human IgG1 that have shown improved pharmacokinetics in non-human primates include the T250Q/M428L mutation (61), the M252Y/ S254T/T256E mutation (62), and the M428L/N434S mutation (63).”
BackgroundReduced elimination of IgG antibodies by engineering the variable region
Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq009 · Cited by 265 · cited 1×
“The second technology is to engineer the variable region to lower the isoelectric point of the antibody in order to reduce the non-specific cellular uptake of the antibody (96).”
BackgroundSelf-citationStructural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259 · cited 2×
“Presumably, this pre-existing antibody is rheumatoid factor, which is known to recognize human IgG1 in the CH2-CH3 interface region.”
BackgroundPivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Ziolkowska, M., Kurowska, M., Radzikowska, A., Luszczykiewicz, G., Wiland, P., Dziewczopolski, W., Filipowicz‐Sosnowska, A., Pazdur, J., Szechinski, J., Kowalczewski, J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10388 · Cited by 200 · cited 1×
“A high concentration of receptor activator of nuclear factor jB ligand in synovial fluid from rheumatoid arthritis patients (86), and of IL-13 in the lung bronchoalveolar lavage fluid from asthma patients (87) are also reported.”
Background
Cited by
Lysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
“So-called sweeping antibodies have a modified pH-sensitive variable domain that releases the target protein into acidic compartments to be digested, and the unbound antibody is recycled back to the cell surface 391 .”
BackgroundConsiderations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
Pance, K., Gramespacher, J. A., Byrnes, J. R., Salangsang, F., Serrano, J.-A. C., Cotton, A. D., Steri, V., & Wells, J. A. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01456-2 · Cited by 265
Extracellular targeted protein degradation: an emerging modality for drug discovery
Wells, J. A., & Kumru, K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00833-z · Cited by 176
“The ratios of transcript level (transcripts per million kilobases, TPM) for PDL1 to RNF43 across three cell lines tested (MDA-MB-231, HCC837 and T24) were 7, 10 and 35, respectively 84 .”
Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
Grevys, A., Frick, R., Mester, S., Flem-Karlsen, K., Nilsen, J., Foss, S., Sand, K. M. K., Emrich, T., Fischer, J. A. A., Greiff, V., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103746 · Cited by 51
“Consequently, less pH-dependent FcRn binding results in rapid accumulation within cells (Vaccaro et al., 2005) and increased clearance of bound antigen (Igawa et al., 2013, 2016; Yang et al., 2017), but also shorter antibody half-life (Dall’Acqua et al., 2002; Gan et al., 2009).”
Cell surface dynamics and cellular distribution of endogenous FcRn
D’Hooghe, L., Chalmers, A. D., Heywood, S., & Whitley, P. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182695 · Cited by 42
Tulika, T., Pedersen, R. W., Rimbault, C., Ahmadi, S., Rivera‐de‐Torre, E., Fernández‐Quintero, M. L., Loeffler, J. R., Bohn, M., Ljungars, A., Ledsgaard, L., et al. (2023) · Protein Science · doi:10.1002/pro.4821 · Cited by 11
Metadata
- Authors
- Igawa, T., Haraya, K., & Hattori, K.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2016-02-10
- Volume
- 270
- Issue
- 1
- Pages
- 132-151
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2298166996
- Cited by
- 101
- References
- 11
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.